Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer

Detalles Bibliográficos
Autores principales: Siddiqui, Tasmiyah, Rani, Payal, Ashraf, Tayyaba, Ellahi, Aayat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577648/
https://www.ncbi.nlm.nih.gov/pubmed/36268293
http://dx.doi.org/10.1016/j.amsu.2022.104665
_version_ 1784811802254639104
author Siddiqui, Tasmiyah
Rani, Payal
Ashraf, Tayyaba
Ellahi, Aayat
author_facet Siddiqui, Tasmiyah
Rani, Payal
Ashraf, Tayyaba
Ellahi, Aayat
author_sort Siddiqui, Tasmiyah
collection PubMed
description
format Online
Article
Text
id pubmed-9577648
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95776482022-10-19 Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer Siddiqui, Tasmiyah Rani, Payal Ashraf, Tayyaba Ellahi, Aayat Ann Med Surg (Lond) Short Communication Elsevier 2022-09-16 /pmc/articles/PMC9577648/ /pubmed/36268293 http://dx.doi.org/10.1016/j.amsu.2022.104665 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Short Communication
Siddiqui, Tasmiyah
Rani, Payal
Ashraf, Tayyaba
Ellahi, Aayat
Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
title Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
title_full Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
title_fullStr Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
title_full_unstemmed Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
title_short Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
title_sort enhertu (fam-trastuzumab-deruxtecan-nxki) – revolutionizing treatment paradigm for her2-low breast cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577648/
https://www.ncbi.nlm.nih.gov/pubmed/36268293
http://dx.doi.org/10.1016/j.amsu.2022.104665
work_keys_str_mv AT siddiquitasmiyah enhertufamtrastuzumabderuxtecannxkirevolutionizingtreatmentparadigmforher2lowbreastcancer
AT ranipayal enhertufamtrastuzumabderuxtecannxkirevolutionizingtreatmentparadigmforher2lowbreastcancer
AT ashraftayyaba enhertufamtrastuzumabderuxtecannxkirevolutionizingtreatmentparadigmforher2lowbreastcancer
AT ellahiaayat enhertufamtrastuzumabderuxtecannxkirevolutionizingtreatmentparadigmforher2lowbreastcancer

Ejemplares similares